title: Current therapies for premature ejaculation.
abstract: Premature ejaculation (PE) subjectively affects 20-30% of men globally. Until recently, understanding of PE was hampered by the absence of a widely accepted definition, paucity of evidence-based clinical studies, and the absence of an appropriate animal model. Here, we elaborate on the current definition of PE, its pathogenesis, currently available therapies, and future treatment prospects. Most treatments for PE are 'off-label' and include selective serotonin reuptake inhibitors (SSRIs), topical anesthetics, tramadol, and phosphodiesterase type 5 (PDE5) inhibitors. Such knowledge of the benefit and limitations of each treatment will help to direct future drug design and formulations.
authors.affiliation: Department of Pharmacology, School of Pharmacy, Ankara University, Ankara, Turkey; Department of Urology, Tulane University Health Sciences Center, New Orleans, LA, USA. Electronic address: serapgur@ankara.edu.t.
authors.forename: Serap
authors.initials: S
authors.lastname: Gur
authors.affiliation: Department of Pharmacology, Tulane University Health Sciences Center, New Orleans, LA, USA.
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Kadowitz
authors.affiliation: Department of Urology, Tulane University Health Sciences Center, New Orleans, LA, USA.
authors.forename: Suresh C
authors.initials: SC
authors.lastname: Sikka
mesh_terms: D000818:Animals; D004542:Ejaculation / Q000502:physiology; D006801:Humans; D061686:Premature Ejaculation / Q000188:drug therapy* / Q000503:physiopathology